Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy
Primary Purpose
Lead, Blood, Pregnancy, Bone Resorption
Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
calcium carbonate
Sponsored by
About this trial
This is an interventional prevention trial for Lead, Blood focused on measuring lead, blood, pregnancy, calcium, randomized trial, dietary supplementation, bone resorption
Eligibility Criteria
Inclusion Criteria:
- being in the first trimester of pregnancy (no more than 14 weeks gestation); not presenting with a high-risk pregnancy; residing and plans to reside in the metropolitan Mexico City area for approximately 5 years; agreeing to participate and signing the informed consent form.
Exclusion Criteria:
- high-risk pregnancy
Sites / Locations
- Mauricio Hernandez-Avila
Arms of the Study
Arm 1
Arm Type
Placebo Comparator
Arm Label
1
Arm Description
Placebo
Outcomes
Primary Outcome Measures
Blood Lead Concentration, Plasma Lead Concentration
Secondary Outcome Measures
Urinary Cross-linked N-telopeptides (marker of bone resorption)
Full Information
NCT ID
NCT00558623
First Posted
November 14, 2007
Last Updated
November 14, 2007
Sponsor
National Institute of Environmental Health Sciences (NIEHS)
Collaborators
Mexican National Institute of Public Health, Brigham and Women's Hospital, University of California, Santa Cruz
1. Study Identification
Unique Protocol Identification Number
NCT00558623
Brief Title
Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy
Official Title
Controlled Trial in Pregnancy of Dietary Supplements for Suppression of Bone Resorption and Mobilization of Lead Into Plasma
Study Type
Interventional
2. Study Status
Record Verification Date
November 2007
Overall Recruitment Status
Completed
Study Start Date
January 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute of Environmental Health Sciences (NIEHS)
Collaborators
Mexican National Institute of Public Health, Brigham and Women's Hospital, University of California, Santa Cruz
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Lead accumulates in bone. During pregnancy, physiologic changes occur prompting bone resorption in order to provide calcium to the growing fetal skeleton also release the lead stored in bone into a pregnant woman's circulation. We have previously demonstrated that lead stores mobilized into the circulation of pregnant women pose a major threat to fetal development. This is particularly unfortunate since bone lead stores, once accumulated, persist for decades, thereby jeopardizing the pregnancies of women even if their current lead exposures have subsided. What then can be done for the many thousands of women who have had lead exposure while growing up and who want to have healthy children? To address this question, in 2000, this project embarked on a randomized intervention trial to test whether a bedtime nutritional supplement of 1,000 mg of calcium can significantly reduce fetal lead exposure and toxicity by suppressing bone resorption in the pregnant mother.
Detailed Description
Recent evidence indicates that there is a marked increase in the mobilization of lead from maternal bone stores into circulation during pregnancy and lactation. Furthermore, data from our group and others indicate that this phenomenon carries a significant risk of fetal toxicity in the form of growth (decreased birth weight, head circumference, birth length) and subsequent cognitive development. These findings pose a major public health problem, even among societies with declining lead exposure, given the persistence of pockets of high lead exposure (including some communities living in proximity to hazardous waste) as well as the long residence time of lead in bone (years to decades). One possible strategy for suppressing the mobilization of maternal bone lead stores during pregnancy is nutritional intervention. We are conducting a randomized, double-blinded, placebo-controlled trial of dietary supplements containing 1,200 milligrams of calcium as a means of suppressing bone resorption and the resulting mobilization of lead from bone into plasma during pregnancy, and into breast milk during the postpartum period. We are taking maternal measurements of pre-pregnancy and postpartum bone lead using our K-x-ray fluorescence technology; bone resorption (by assaying N-telopeptide of type I collagen in urine [urinary NTX]), whole blood lead, and plasma lead (using special collection techniques and measured by IDTIMS) during pre-pregnancy, the first, second, third trimesters and at one and four months postpartum; and breast milk lead levels at one and four months postpartum.
We are measuring maternal plasma and breast milk lead levels as these are the most direct sources of fetal and infant lead exposures, and recent research suggests that maternal venous blood lead levels do not adequately reflect either of these parameters. We are testing the hypothesis that supplements will significantly decrease urinary NTX, plasma lead, and breast milk lead levels. We are also exploring the relationship of plasma lead levels to birth anthropometry measures. This research, if successful, may provide a means of preventing secondary toxicity from accumulated lead burdens among women of reproductive age.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lead, Blood, Pregnancy, Bone Resorption
Keywords
lead, blood, pregnancy, calcium, randomized trial, dietary supplementation, bone resorption
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
670 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
calcium carbonate
Other Intervention Name(s)
Lederle, Inc.
Intervention Description
daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
Primary Outcome Measure Information:
Title
Blood Lead Concentration, Plasma Lead Concentration
Time Frame
2nd, 3rd trimester pregnancy and 1,4,7,12 months postpartum
Secondary Outcome Measure Information:
Title
Urinary Cross-linked N-telopeptides (marker of bone resorption)
Time Frame
2nd, 3rd trimester of pregnancy and 1,4,7,12 months postpartum
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
being in the first trimester of pregnancy (no more than 14 weeks gestation); not presenting with a high-risk pregnancy; residing and plans to reside in the metropolitan Mexico City area for approximately 5 years; agreeing to participate and signing the informed consent form.
Exclusion Criteria:
high-risk pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Howard Hu, MD, ScD
Organizational Affiliation
Harvard School of Public Health and University of Michigan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mauricio Hernandez-Avila, MD, ScD
Organizational Affiliation
National Institute of Public Health and Ministry of Health, Mexico
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mauricio Hernandez-Avila
City
Cuernavaca
State/Province
Morelos
ZIP/Postal Code
62100
Country
Mexico
12. IPD Sharing Statement
Citations:
PubMed Identifier
31455712
Citation
Perng W, Tamayo-Ortiz M, Tang L, Sanchez BN, Cantoral A, Meeker JD, Dolinoy DC, Roberts EF, Martinez-Mier EA, Lamadrid-Figueroa H, Song PXK, Ettinger AS, Wright R, Arora M, Schnaas L, Watkins DJ, Goodrich JM, Garcia RC, Solano-Gonzalez M, Bautista-Arredondo LF, Mercado-Garcia A, Hu H, Hernandez-Avila M, Tellez-Rojo MM, Peterson KE. Early Life Exposure in Mexico to ENvironmental Toxicants (ELEMENT) Project. BMJ Open. 2019 Aug 26;9(8):e030427. doi: 10.1136/bmjopen-2019-030427.
Results Reference
derived
PubMed Identifier
25511814
Citation
Ettinger AS, Lamadrid-Figueroa H, Mercado-Garcia A, Kordas K, Wood RJ, Peterson KE, Hu H, Hernandez-Avila M, Tellez-Rojo MM. Effect of calcium supplementation on bone resorption in pregnancy and the early postpartum: a randomized controlled trial in Mexican women. Nutr J. 2014 Dec 16;13(1):116. doi: 10.1186/1475-2891-13-116.
Results Reference
derived
Learn more about this trial
Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy
We'll reach out to this number within 24 hrs